Department of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Department of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
Mol Genet Metab. 2024 Sep-Oct;143(1-2):108573. doi: 10.1016/j.ymgme.2024.108573. Epub 2024 Aug 30.
Cohort data on continuous glucose monitoring (CGM) metrics are scarce for liver glycogen storage diseases (GSDs) and idiopathic ketotic hypoglycemia (IKH). The aim of this study was to retrospectively describe CGM metrics for people with liver GSDs and IKH.
CGM metrics (descriptive, glycemic variation and glycemic control parameters) were calculated for 47 liver GSD and 14 IKH patients, categorized in cohorts by disease subtype, age and treatment status, and compared to published age-matched CGM metrics from healthy individuals. Glycemic control was assessed as time-in-range (TIR; ≥3.9 - ≤7.8 and ≥3.9 - ≤10.0 mmol/L), time-below-range (TBR; <3.0 mmol/L and ≥3.0 - ≤3.9 mmol/L), and time-above-range (TAR; >7.8 and >10.0 mmol/L).
Despite all patients receiving dietary treatment, GSD cohorts displayed significantly different CGM metrics compared to healthy individuals. Decreased TIR together with increased TAR were noted in GSD I, GSD III, and GSD XI (Fanconi-Bickel syndrome) cohorts (all p < 0.05). In addition, all GSD I cohorts showed increased TBR (all p < 0.05). In GSD IV an increased TBR (p < 0.05) and decreased TAR were noted (p < 0.05). In GSD IX only increased TAR was observed (p < 0.05). IKH patient cohorts, both with and without treatment, presented CGM metrics similar to healthy individuals.
Despite dietary treatment, most liver GSD cohorts do not achieve CGM metrics comparable to healthy individuals. International recommendations on the use of CGM and clinical targets for CGM metrics in liver GSD patients are warranted, both for patient care and clinical trials.
关于连续血糖监测(CGM)指标的数据在肝糖原贮积病(GSD)和特发性酮症性低血糖(IKH)中很少见。本研究的目的是回顾性描述肝 GSD 和 IKH 患者的 CGM 指标。
对 47 例肝 GSD 和 14 例 IKH 患者的 CGM 指标(描述性、血糖变化和血糖控制参数)进行了计算,并按疾病亚型、年龄和治疗状态进行分类,与健康个体的已发表年龄匹配的 CGM 指标进行了比较。血糖控制评估为时间在范围内(TIR;≥3.9 - ≤7.8 和≥3.9 - ≤10.0mmol/L)、时间在范围内(TBR;<3.0mmol/L 和≥3.0 - ≤3.9mmol/L)和时间在范围外(TAR;>7.8 和>10.0mmol/L)。
尽管所有患者均接受饮食治疗,但与健康个体相比,GSD 组的 CGM 指标仍存在显著差异。GSD I、GSD III 和 GSD XI(范可尼-比克尔综合征)组均显示 TIR 降低,TAR 增加(均 p < 0.05)。此外,所有 GSD I 组均显示 TBR 增加(均 p < 0.05)。GSD IV 组观察到 TBR 增加(p < 0.05)和 TAR 降低(p < 0.05)。GSD IX 组仅观察到 TAR 增加(p < 0.05)。有和没有治疗的 IKH 患者组的 CGM 指标与健康个体相似。
尽管进行了饮食治疗,但大多数肝 GSD 组仍无法达到与健康个体相当的 CGM 指标。有必要制定肝 GSD 患者使用 CGM 的国际建议和 CGM 指标的临床目标,以进行患者护理和临床试验。